Immunotherapy of neonatal septicemia

M. C. Yoder, R. A. Polin

Research output: Contribution to journalArticle

25 Scopus citations


This chapter has reviewed the deficiencies in immune defense that place the neonate, particularly the premature infant, at increased risk of invasive bacterial disease. We also have reviewed the literature on the rationale for exchange transfusion, granulocyte transfusion, intravenous immunoglobulin, and fibronectin administration as immunotherapeutic agents in infected infants. There have been no randomized controlled trials of exchange transfusion, immunoglobulin, or fibronectin administration in human infants with infection. Granulocyte transfusion in the infected newborn infant has been studied in a controlled fashion, but the results of clinical trials are conflicting. Thus, all of these interventions appear to need further evaluation. We therefore recommend that in the septic newborn infant with neutropenia and an I/T ratio ≥ 0.8, who fails to demonstrate a favorable response to conventional antibacterial chemotherapy and cardiopulmonary support, the administration of approximately 1 x 109 irradiated granulocytes per kg may be beneficial. In the absence of equipment to isolate the granulocytes, a double-volume exchange transfusion with fresh heparinized whole blood will provide a similar quantity of functional phagocytes.

Original languageEnglish (US)
Pages (from-to)481-501
Number of pages21
JournalPediatric Clinics of North America
Issue number3
StatePublished - Jan 1 1986

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Immunotherapy of neonatal septicemia'. Together they form a unique fingerprint.

  • Cite this